CTXR logo

CTXR
Citius Pharmaceuticals Inc

21,468
Mkt Cap
$17.23M
Volume
3.03M
52W High
$2.48
52W Low
$0.63
PE Ratio
-0.27
CTXR Fundamentals
Price
$0.77
Prev Close
$0.933
Open
$0.78
50D MA
$0.8047
Beta
1.45
Avg. Volume
828,196.91
EPS (Annual)
-$3.38
P/B
0.22
Rev/Employee
$0.00
$21.26
Loading...
Loading...
News
all
press releases
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules Citius Pharmaceuticals Announces Closing of Registered Direct Offering of...
PR Newswire·2d ago
News Placeholder
More News
News Placeholder
What's Behind The Drop In Citius Pharmaceuticals?
Citius Pharmaceuticals (NASDAQ:CTXR) shares tumbled on Friday after it announced a registered direct offering, raising dilution concerns.read more...
Benzinga·2d ago
News Placeholder
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced...
PR Newswire·2d ago
News Placeholder
Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development
Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting...
PR Newswire·26d ago
News Placeholder
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts PR Newswire CRANFORD...
PR Newswire·1mo ago
News Placeholder
Citius Oncology Announces Positive Topline Results from InvestigatorInitiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
Citius Oncology Announces Positive Topline Results from InvestigatorInitiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers Citius Oncology...
PR Newswire·2mo ago
News Placeholder
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CART Therapy in HighRisk Diffuse Large BCell Lymphoma
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CART Therapy in HighRisk Diffuse Large BCell Lymphoma Citius Oncology Announces...
PR Newswire·2mo ago
News Placeholder
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program PR...
PR Newswire·2mo ago
News Placeholder
Citius Pharmaceuticals Q1 Earnings Report: What Investors Need to Know
read more...
Benzinga·2mo ago
News Placeholder
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR PR Newswire...
PR Newswire·2mo ago
<
1
2
...
>

Latest CTXR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.